KLK5 gene expression is severely upregulated in androgen-independent prostate cancer cells after treatment with the chemotherapeutic agents docetaxel and mitoxantrone

Biological Chemistry

Volumn 391, Issue 4, 2010, Pages 467-474

  Mavridis, Konstantinos ^a   Talieri, Maroulio ^b   Scorilas, Andreas ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b SAINT SAVVAS HOSPITAL   (Greece)

Author keywords

Chemotherapy; Kallikrein related peptidases; KLK5; Prostate cancer; PSA; Treatment monitoring

Indexed keywords

DOCETAXEL; KALLIKREIN 5; MESSENGER RNA; MITOXANTRONE; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

CANCER CELL CULTURE; CONFERENCE PAPER; CONTROLLED STUDY; GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; KLK5 GENE; NUCLEOTIDE SEQUENCE; PATIENT MONITORING; PRIORITY JOURNAL; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION;

ANDROGENS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CYTOSTATIC AGENTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KALLIKREINS; MALE; MITOXANTRONE; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TAXOIDS; TIME FACTORS; UP-REGULATION;

EID: 77951466605     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/BC.2010.026     Document Type: Conference Paper

References (35)

1. Berry, W.R. (2005). The evolving role of chemotherapy in androgenindependent (hormone-refractory) prostate cancer. Urology 65, 2-7.
2. Boland, M.P., Fitzgerald, K.A., and O'Neill, L.A. (2000). Topoisomerase II is required for mitoxantrone to signal nuclear factor kB activation in HL60 cells. J. Biol. Chem. 275, 25231-25238.
3. Borgono, C.A., Michael, I.P., and Diamandis, E.P. (2004). Human tissue kallikreins: physiologic roles and applications in cancer. Mol. Cancer Res. 2, 257-280.
4. Bruckheimer, E.M. and Kyprianou, N. (2000). Apoptosis in prostate carcinogenesis. A growth regulator and a therapeutic target. Cell Tissue Res. 301, 153-162.
5. Bryant, R.J. and Hamdy, F.C. (2008). Screening for prostate cancer: an update. Eur. Urol. 53, 37-44.
6. Cheung, R., Tucker, S.L., and Kuban, D.A. (2006). First-year PSA kinetics and minima after prostate cancer radiotherapy are predictive of overall survival. Int. J. Radiat. Oncol. Biol. Phys. 66, 20-24.
7. Collins, R., Trowman, R., Norman, G., Light, K., Birtle, A., Fenwick, E., Palmer, S., and Riemsma, R. (2006). A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer. Br. J. Cancer 95, 457-462.
8. Diamandis, E.P. and Yousef, G.M. (2002). Human tissue kallikreins: a family of new cancer biomarkers. Clin. Chem. 48, 1198-1205.
9. Duffy, M., McGowan, P., and Gallagher, W. (2008). Cancer invasion and metastasis: changing views. J. Pathol. 214, 283-293.
10. Emami, N. and Diamandis, E.P. (2008). Utility of kallikrein-related peptidases (KLKs) as cancer biomarkers. Clin. Chem. 54, 1600-1607.
11. Fleming, M.T., Morris, M.J., Heller, G., and Scher, H.I. (2006). Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials. Nat. Clin. Pract. Oncol. 3, 658-667.
12. Floros, K.V., Thomadaki, H., Katsaros, N., Talieri, M., and Scorilas, A. (2004). mRNA expression analysis of a variety of apoptosisrelated genes, including the novel gene of the BCL2-family, BCL2L12, in HL-60 leukemia cells after treatment with carboplatin and doxorubicin. Biol. Chem. 385, 1099-1103.
13. Gulley, J. and Dahut, W.L. (2004). Chemotherapy for prostate cancer: finally an advance! Am. J. Ther. 11, 288-294.
14. Hadaschik, B.A. and Gleave, M.E. (2007). Therapeutic options for hormone-refractory prostate cancer in 2007. Urol. Oncol. 25, 413-419.
15. Korbakis, D., Gregorakis, A.K., and Scorilas, A. (2009). Quantitative analysis of human kallikrein 5 (KLK5) expression in prostate needle biopsies: an independent cancer biomarker. Clin. Chem. 55, 904-913.
16. Lassi, K. and Dawson, N.A. (2009). Emerging therapies in castrateresistant prostate cancer. Curr. Opin. Oncol. 21, 260-265.
17. Lieberman, R. (2004). Evidence-based medical perspectives: the evolving role of PSA for early detection, monitoring of treatment response, and as a surrogate end point of efficacy for interventions in men with different clinical risk states for the prevention and progression of prostate cancer. Am. J. Ther. 11, 501-506.
18. Livak, K.J. and Schmittgen, T.D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-DDCT) method. Methods 25, 402-408.
19. Lundwall, A. and Brattsand, M. (2008). Kallikrein-related peptidases. Cell. Mol. Life Sci. 65, 2019-2038.
20. Obiezu, C.V. and Diamandis, E.P. (2005). Human tissue kallikrein gene family: applications in cancer. Cancer Lett. 224, 1-22.
21. Paliouras, M. and Diamandis, E.P. (2006). The kallikrein world: an update on the human tissue kallikreins. Biol. Chem. 387, 643-652.
22. Pienta, K.J. and Smith, D.C. (2005). Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J. Clin. 55, 300-318; quiz 323-325.
23. Revelos, K., Petraki, C., Scorilas, A., Stefanakis, S., Malovrouvas, D., Alevizopoulos, N., Kanellis, G., Halapas, A., and Koutsilieris, M. (2007). Correlation of androgen receptor status, neuroendocrine differentiation and angiogenesis with time-to-biochemical failure after radical prostatectomy in clinically localized prostate cancer. Anticancer Res. 27, 3651-3660.
24. Reynolds, M.A., Kastury, K., Groskopf, J., Schalken, J.A., and Rittenhouse, H. (2007). Molecular markers for prostate cancer. Cancer Lett. 249, 5-13.
25. Richter, E., Srivastava, S., and Dobi, A. (2007). Androgen receptor and prostate cancer. Prostate Cancer Prostatic Dis. 10, 114-118.
26. Schmitt, M. and Magdolen, V. (2009). Using kallikrein-related peptidases (KLK) as novel cancer biomarkers. Thromb. Haemost. 101, 222-224.
27. Schmittgen, T.D. and Livak, K.J. (2008). Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 3, 1101-1108.
28. Sotiropoulou, G., Pampalakis, G., and Diamandis, E.P. (2009). Functional roles of human kallikrein-related peptidases. J. Biol. Chem. 284, 32989-32994.
29. Thomadaki, H. and Scorilas, A. (2008). Molecular profile of breast versus ovarian cancer cells in response to treatment with the anticancer drugs cisplatin, carboplatin, doxorubicin, etoposide and taxol. Biol. Chem. 389, 1427-1434.
30. Thomadaki, H., Mavridis, K., Talieri, M., and Scorilas, A. (2009). Treatment of PC3 prostate cancer cells with mitoxantrone, etoposide, doxorubicin and carboplatin induces distinct alterations in the expression of kallikreins 5 and 11. Thromb. Haemost. 101, 373-380.
31. Tomlins, S.A., Rubin, M.A., and Chinnaiyan, A.M. (2006). Integrative biology of prostate cancer progression. Annu. Rev. Pathol. 1, 243-271.
32. Van Poppel, H. (2005). Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer. Can. J. Urol. 12 (Suppl. 1), 81-85.
33. Van Poppel, H., Joniau, S., Van Cleynenbreugel, B., Mottaghy, F.M., and Oyen, R. (2009). Diagnostic evaluation of PSA recurrence and review of hormonal management after radical prostatectomy. Prostate Cancer Prostatic Dis. 12, 116-123.
34. Yousef, G.M., Chang, A., Scorilas, A., and Diamandis, E.P. (2000). Genomic organization of the human kallikrein gene family on chromosome 19q13.3-q13.4. Biochem. Biophys. Res. Commun. 276, 125-133.
35. Yousef, G.M., Scorilas, A., Chang, A., Rendl, L., Diamandis, M., Jung, K., and Diamandis, E.P. (2002). Down-regulation of the human kallikrein gene 5 (KLK5) in prostate cancer tissues. Prostate 51, 126-132.